Table 3.
Summary of molecular changes in the tumor on serial biopsy
| Patient # |
V- Dose (mg BID) |
ER/PR | # of Cycles |
BR | PFS (months) |
Ac. K69 Hsp90 |
Hsp90 | Hsp70 | c-Raf | AKT | pAKT | Ac. α- tubulin |
P27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 001 | 200 | +/− | 12 | PR | 20.7 | ↑ | NC | ↑ | ND | ? | ND | ND | ND |
| 010 | 300 | +/+ | 8 | PR | 7.6 | ↑ | ND | ↑ | ND | ND | ND | ND | ND |
| 051 | 300 | −/− | 9 | SD | 8.9 | ↑ | NC | NC | ? | NC | ? | ↑ | ↑ |
| 052 | 300 | −/− | 3 | PR | 15.7 | ↑ | NC | ↑ | NC | NC | NC | ↑ | ↑ |
| 053 | 300 | +/− | 1 | NE | 14.0 | ↑ | NC | ↑ | NC | NC | NC | ↑ | ↑ |
| 054 | 300 | −/− | 6 | PR | 13.8 | ↑ | NC | NC | NC | NC | NC | ↑ | ↑ |
| 055 | 300 | −/− | 6 | SD | 5.6 | ND | NC | ↑ | NC | NC | NC | ↑ | ↑ |
V: Vorinostat; ER/PR: Estrogen and Progesterone receptor; BR: Best Response; PR: Partial Response; SD Stable Disease; NE: Non-evaluable; PFS: Progression-Free Survival; PBMC: Peripheral Blood Mononuclear Cells; Ac: Acetylation; NC: No change; ND: Not done